✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Jubilant Pharmova Ltd.

JUBLPHARMA

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹17,030 Cr.
P/E
35.65

Jubilant Pharmova Ltd.

  • Jubilant Pharmova
  • Alembic Pharma
  • Natco Pharma
  • TJI Pharma - API & CRAMS

FAQs on Jubilant Pharmova Ltd. Shareprice

Jubilant Pharmova has given lower returns compared to its competitors.
Jubilant Pharmova has grown at ~5.78% over the last 8yrs while peers have grown at a median rate of 10.54%

Jubilant Pharmova is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Jubilant Pharmova is 35.96, while 3 year average PE is 45.88.
Also latest EV/EBITDA of Jubilant Pharmova is 15.16 while 3yr average is 12.26.

View FAQ's On Business

Growth Table

  • Jubilant Pharmova Ltd.
  • Alembic Pharma
  • Natco Pharma

Balance Sheet

  • Jubilant Pharmova Ltd.
  • Alembic Pharma
  • Natco Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Jubilant Pharmova Ltd.
  • Alembic Pharma
  • Natco Pharma

Cash Flow

  • Jubilant Pharmova Ltd.
  • Alembic Pharma
  • Natco Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Jubilant Pharmova Ltd.
  • Alembic Pharma
  • Natco Pharma

Quarterly Results

  • Jubilant Pharmova Ltd.
  • Alembic Pharma
  • Natco Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Jubilant Pharmova Ltd. Financials

Balance sheet of Jubilant Pharmova is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Jubilant Pharmova is increasing.
Latest net debt of Jubilant Pharmova is ₹1,975 Crs as of Sep-25.
This is greater than Mar-25 when it was ₹259 Crs.

The profit is oscillating.
The profit of Jubilant Pharmova is ₹475 Crs for TTM, ₹839 Crs for Mar 2025 and ₹77.1 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Jubilant Pharmova latest dividend payout ratio is 9.41% and 3yr average dividend payout ratio is 55.94%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech